These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32141721)

  • 1. The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
    Gopalakrishnan M; Zhu H; Farchione TR; Mathis M; Mehta M; Uppoor R; Younis I
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
    Younis IR; Gopalakrishnan M; Mathis M; Mehta M; Uppoor R; Zhu H; Farchione T
    JAMA Psychiatry; 2020 Oct; 77(10):1064-1071. PubMed ID: 32609294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
    Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
    Chen YF; Wang SJ; Khin NA; Hung HM; Laughren TP
    Pharm Stat; 2010; 9(3):217-29. PubMed ID: 20872622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
    Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
    Earley W; Guo H; Daniel D; Nasrallah H; Durgam S; Zhong Y; Patel M; Barabássy Á; Szatmári B; Németh G
    Schizophr Res; 2019 Feb; 204():282-288. PubMed ID: 30172595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response.
    Leucht S; Chaimani A; Leucht C; Huhn M; Mavridis D; Helfer B; Samara M; Cipriani A; Geddes JR; Salanti G; Davis JM
    Schizophr Res; 2018 Nov; 201():315-323. PubMed ID: 29804928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.
    Weiser M; Levi L; Zamora D; Biegon A; SanGiovanni JP; Davidson M; Burshtein S; Gonen I; Radu P; Slobozean Pavalache K; Nastas I; Hemi R; Ryan T; Davis JM
    JAMA Psychiatry; 2019 Oct; 76(10):1009-1017. PubMed ID: 31365044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials.
    Kalaria SN; Zhu H; Farchione TR; Mathis MV; Gopalakrishnan M; Uppoor R; Mehta M; Younis I
    Clin Pharmacol Ther; 2019 Nov; 106(5):1046-1055. PubMed ID: 31069784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):144-52. PubMed ID: 23473810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.
    Kubo K; Fleischhacker WW; Suzuki T; Yasui-Furukori N; Mimura M; Uchida H
    Acta Psychiatr Scand; 2019 Feb; 139(2):108-116. PubMed ID: 30198163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data.
    Matsusaki A; Kaneko M; Narukawa M
    Clin Drug Investig; 2018 Aug; 38(8):751-761. PubMed ID: 29858840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
    Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
    J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.